Hermès closed the week down 3.2% in Paris after a month in which investors began questioning whether a 38x forward earnings multiple—roughly 12 turns above LVMH's 26x and 19 turns above Kering's beleaguered 19x—still reflects operating reality. The stock trades at €2,340 per share, valuing the house at roughly €250 billion, making it the second-largest luxury group by market capitalisation. The repricing is not about deterioration. It is about deceleration.

Hermès reported 11.3% organic revenue growth in the fourth quarter, ahead of LVMH's 3% and Kering's flat performance, but below the 15-18% quarterly cadence investors had priced in through mid-2024. Greater China, which accounts for 31% of group sales, grew 6.8% in constant currency during the quarter, down from 12.4% in the prior period. Mainland China growth, excluding Hong Kong and Macau, slowed to 4.1%. The deceleration was not unexpected—luxury analysts had flagged softening mainland consumption in October—but it arrived in the same quarter that LVMH's wines and spirits division contracted 8% and Kering's Gucci brand posted its seventh consecutive quarter of decline. The context matters. Hermès is still gaining share, but the sector backdrop no longer supports a premium that assumes structural immunity.

The valuation wedge between Hermès and its peers widened through 2023 on the thesis that the house's scarcity model—waitlists for Birkin and Kelly bags, no discounting, limited wholesale exposure—insulated it from the promotional activity and inventory glut afflicting LVMH's Dior and Louis Vuitton franchises. That thesis has not broken. But it is being stress-tested. Hermès maintains 68% gross margins versus LVMH's 66% and Kering's 63%, and its leather goods category—47% of sales—posted 14% growth in the quarter, still the fastest in the sector. The question allocators are now asking is whether that 12-turn premium to LVMH is justified when both houses face the same Chinese real-estate overhang, the same aspirational-consumer pullback, and the same unfavourable base effects from 2021-2022's pandemic rebound. Worth noting: Hermès has never traded below 30x forward earnings in the past five years, even during the March 2020 drawdown. The current multiple of 38x is elevated but not anomalous. It is the *rate of change* in Chinese growth that is forcing the reassessment.

Operators should watch three follow-on events over the next 90 days. First, Hermès will report full-year 2024 results in early March; consensus expects 12.8% organic growth, but any guidance below 10% for 2025 will likely trigger further multiple compression. Second, LVMH reports February 4, and if its fashion and leather goods division—48% of group revenue—posts mid-single-digit growth, the narrative that Hermès is structurally immune weakens further. Third, Chinese New Year spending data will be published by late February; last year's holiday period saw a 6% uptick in luxury purchases, but early credit-card data from UnionPay suggests this year's lift may be closer to 3-4%.

The stock is not broken. It is being priced with precision instead of faith.